Research programme: recombinant protein subunit vaccines - Hawaii Biotech

Drug Profile

Research programme: recombinant protein subunit vaccines - Hawaii Biotech

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Hawaii Biotech
  • Class Parasitic vaccines; Recombinant proteins; Subunit vaccines; Viral envelope proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Zika virus infection
  • Research Crimean-Congo haemorrhagic fever virus infections
  • No development reported Encephalitis virus infections; Malaria

Most Recent Events

  • 30 Aug 2016 Hawaii Biotech receives SBIR grant from National Institute of Allergy and Infectious Disease (NIAID) for vaccine development in Chikungunya
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Encephalitis-virus-infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top